Professor, Departments of Pharmacy and Global Health, University of Washington, Seattle
Louis P. Garrison, Jr., PhD, is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. He also co-directs the Global Medicines Program in Global Health.
Dr. Garrison’s career began with 13 years in non-profit health policy research at the Battelle Human Affairs Research Centers (Seattle), and at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, and was based in Basel, Switzerland.
Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 100 publications in peer-reviewed journals. His research interests include national and international health policy issues related to personalized medicine, benefit-risk analysis, insurance, pricing, reimbursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.
From 2007-2009, Dr. Garrison served on the ISPOR Board of Directors. He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements, and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. He is faculty advisor for the UW ISPOR Student Chapter, and is ISPOR President-elect for 2016-17.
1 blog from the author
Posted on 27.10.2015
Public and private healthcare payers around the world face substantial and evolving challenges in making good decisions on behalf of their ultimate clients—their beneficiaries or subscribers, i.e., people who are at risk of becoming patients. As agents for these potential patients, payers and providers must make prudent clinical and economic recommendations on how to obtain […]